Results 91 to 100 of about 335,217 (205)

Individual heat map assessments demonstrate vestronidase alfa treatment response in a highly heterogeneous mucopolysaccharidosis VII study population. [PDF]

open access: yes, 2019
Mucopolysaccharidosis (MPS) VII is an ultra-rare, progressively debilitating, life-threatening lysosomal disease caused by deficiency of the enzyme, β-glucuronidase. Vestronidase alfa is an approved enzyme replacement therapy for MPS VII. UX003-CL301 was
Bauer, Mislen   +7 more
core   +1 more source

Morquio Syndrome from a Dentist's aspect

open access: yes, 2022
Morquio syndrome is a rare autosomal recessive inherited disease of lysosomal storage defect associated with multiorgan involvement and symptoms are seen due to excessive accumulation of Glucose-aminoglycans in the affected sites. Its characteristic features are extremely abnormal gait, short stature, short neck, and macrocephaly which can be ...
openaire   +1 more source

Aortic Valve Replacement in a Patient with Morquio Syndrome

open access: yesThe Heart Surgery Forum, 2008
Cardiac involvement in Morquio syndrome, mucopolysaccharidosis IV, is characterized by aortic and mitral valve thickening and infiltration of the coronary arteries. There are few reports concerning surgical interventions in patients with mucopolysaccharidoses.
NICOLINI, Francesco   +3 more
openaire   +2 more sources

Clinical utility of comprehensive gene panel testing for common and rare causes of skeletal dysplasia and other skeletal disorders: Results from the largest cohort to date

open access: yesAmerican Journal of Medical Genetics Part A, Volume 194, Issue 9, September 2024.
Abstract Molecular genetics enables more precise diagnoses of skeletal dysplasia and other skeletal disorders (SDs). We investigated the clinical utility of multigene panel testing for 5011 unrelated individuals with SD in the United States (December 2019–April 2022).
Gretchen MacCarrick   +13 more
wiley   +1 more source

Morquio A Syndrome Case Report and Literature Review

open access: yesScholars Journal of Medical Case Reports, 2023
Morquio A syndrome is an autosomal recessive disorder, one of 50 lysosomal storage diseases (LSDs), and is caused by the deficiency of N-acetylgalactosamine-6-sulfate sulfatase (GALNS). Deficiency of this enzyme causes specific glycosaminoglycan (GAG) accumulation: keratan sulfate (KS) and chondroitin-6-sulfate (C6S).
Jaouaher M   +4 more
openaire   +1 more source

Pain management challenges in a patient with mucopolysaccharidosis IVA

open access: yesClinical Case Reports, Volume 12, Issue 8, August 2024.
Key Clinical Message It is important to consider all potential pain management modalities including alternative treatment on managing complex pain presentations. Acupuncture is a treatment modality that may result in reduction of pain in patients with significant medical comorbidities due to MPS IVA.
Marcus Gurgius   +2 more
wiley   +1 more source

Virchow-Robin spaces : an anatomic variant or a pathologic sign? [PDF]

open access: yes, 2009
Virchow-Robin spaces surround blood vessels. Their walls are formed by prolongations of the pia mater and they have no communication with the subarachnoid space. VRS are often seen as well-delineated foci of cerebrospinal fluid signal on MR images.

core  

Patient and family experiences of lysosomal storage diseases in Canada: A qualitative interview study

open access: yesJIMD Reports, Volume 65, Issue 2, Page 63-84, March 2024.
Abstract Canadian patients and families affected by rare genetic lysosomal storage diseases (LSDs) suffer from numerous challenges related to disease management, including issues navigating healthcare and social support services, access to orphan drugs, and intensive treatment regimens.
Nahya Awada, Martin Holcik
wiley   +1 more source

Roentgenographic diagnosis of mucopolysaccharidosis with particular reference to Morquio syndrome

open access: yesSouth African Journal of Radiology, 2012
Mucopolysaccharidosis (MPS) comprises a group of conditions associated with an abnormality in glycoprotein or mucopolysaccharides metabolism. Types of MPS identified are MPS I-H (Hurler's syndrome, gargoylism), MPS II (Hunter's syndrome), MPS III ...
umesh chandra parashari   +3 more
doaj   +1 more source

Morquio A syndrome and effect of enzyme replacement therapy in different age groups of Turkish patients: a case series

open access: yesOrphanet Journal of Rare Diseases, 2021
Background This case series includes longitudinal clinical data of ten patients with Morquio A syndrome from south and southeastern parts of Turkey, which were retrospectively collected from medical records.
Sebile Kılavuz   +8 more
doaj   +1 more source

Home - About - Disclaimer - Privacy